iX Biopharma Ltd.
42C.SI
Stock Exchange of Singapore0.37
SGD
- -
- -
iX Biopharma Ltd.
42C.SI
(Stock Exchange of Singapore)
Recent
price
0.37
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- iX Biopharma Ltd is a specialty pharmaceutical and nutraceutical company that focuses on the development, manufacturing, and commercialization of therapies primarily targeting acute and breakthrough pain management as well as other chronic health conditions. The company operates through two main segments: Specialty Pharmaceuticals and Nutraceuticals. Its core pharmaceutical products include Wafermine, a sublingual ketamine wafer for pain and depression; BnoX, a sublingual buprenorphine wafer for moderate to severe pain; Wafesil, a sublingual sildenafil wafer for erectile dysfunction; Silcap for male erectile dysfunction; Xativa, a sublingual cannabidiol wafer; and Hypera, a sublingual tetrahydrocannabinol wafer addressing chronic pain, anxiety, and insomnia. The nutraceutical portfolio features products such as SL-NAD+, a sublingual NAD+ wafer designed to enhance cellular NAD+ levels, increase energy, and improve alertness, as well as LumeniX, a sublingual glutathione wafer marketed for skin brightening and immune support. Additional pipeline products include iXB 120 for acute agitation, IXB-214 for complex regional pain syndrome, and IXB-314 for treatment-resistant depression, all having completed Phase I clinical trials. The company also pursues drug development in areas like Type 2 Diabetes, Obesity, sarcopenia, and viral prophylaxis using its proprietary WaferiX drug delivery platform technology. Founded in 2004, iX Biopharma is headquartered in Singapore and operates commercially in markets including Singapore, the United States, China, Australia, and New Zealand. Significant recent company developments include the establishment of a capital-light strategic joint venture with U.S.-based Orion Specialty Labs to accelerate commercialization and manufacturing of the WaferiX portfolio in the United States, unlocking immediate access to the large U.S. healthcare market through Orion’s compounding networks. In 2025, iX Biopharma secured S$6.7 million in funding earmarked to support its U.S. market expansion. The company also reported a 39% revenue increase and a 33% reduction in operating cash burn for the half-year ended December 2024, reflecting strong sales growth particularly in the Specialty Pharmaceuticals segment and ongoing operational efficiencies. Furthermore, iX Biopharma expanded its pipeline by launching a program to develop a sublingual dexmedetomidine wafer aimed at treating agitation in dementia and other indications, highlighting a strategic extension into new therapeutic areas using its WaferiX technology. The company has also entered a collaboration with medicinal cannabis company Organic Genetics Group Limited to supply novel sublingual medicinal cannabis wafers in New Zealand, broadening its commercial partnerships within the Asia-Pacific region. Overall, iX Biopharma leverages its proprietary WaferiX sublingual drug delivery platform to develop and commercialize innovative pharmaceutical and nutraceutical products targeting central nervous system disorders, pain management, and various chronic conditions across multiple international markets. Its product pipeline, strategic partnerships, recent capital raises, and operational improvements position the company for growth and enhanced market penetration globally.